摘要
目的:评价3种方案治疗慢性乙型肝炎的经济效果。方法:116例慢性乙型肝炎患者随机分为A、B、C组,A组(n=38)给予拉米夫定100mg.d-1,po;B组(n=38)给予干扰素α-2b(IFNα-2b)300万IU.d-1,im,4周后改为隔日1次im300万IU;C组(n=40)给予IFNα-2b+拉米夫定治疗,剂量、方法同A、B组。3组疗程均为6个月。运用药物经济学原理比较其成本-效果。结果:A、B、C组成本分别为3420、12168、15588元,HBV-DNA转阴率分别为44.7%、47.4%、67.5%。在方案A的基础上,每再获得一个单位效果,方案B、C所需追加的成本依次为324000.00、53368.42元。结论:方案C较佳。
OBJECTIVE： To evaluate the economic effects of three therapeutic schemes for chronic hepatitis B. METHODS： 116 patients with chronic hepatitis B were divided into 3 groups： Group A （n =38） received lamivudine （100 mg · d^ -1, po） for 6 months; Group B （n = 38） received IFNα- 2b （3million IU · d ^-1, ira） for 4 weeks followed by IFNα- 2b （ira, 3million IU, qod） ; Group C （n = 40） received IFNα- 2b （3million IU · d^ -1, im） for 4 weeks followed by IFNα- 2b （ira, 3million IU, qod） plus lamivudine （po, 100 mg · d^ -1） . The course of treatment for the three groups all lasted for 6 months. The cost- effectiveness of the three groups was evaluated using the principle of pharmacoeconomics. RESULTS： In A, B, and C groups, the costs were 3 420, 12 168 and 15 588 Yuan, respectively, and the HBV-DNA negative changing rates were 44.7% , 47.4% and 67.5% , respectively. The increment in cost for one more unit of effectiveness was 324 000.00 Yuan in Group B and 53 368.42 Yuan in Group C as compared with Group A. CONCLUSION： Scheme C is the optimal one pharmacoeconoically.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第29期2247-2249,共3页
China Pharmacy
